Our results suggest that the amount of olaparib, despite being far lower than that used for therapy, could markedly influence PARP1-3 expression levels, which could in turn influence radiolabelled PARP inhibitor uptake levels in the tumour, despite the short timeframe (2 h post-injection); (2) Saturation of PARP inhibitor binding pockets occurs at higher injected masses. The gene discussed is PARP1; the disease is neoplasm.